Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules

J Immunol. 2004 Mar 1;172(5):2845-52. doi: 10.4049/jimmunol.172.5.2845.

Abstract

Targeting recycling endocytic receptors with specific Abs provides a means for introducing a variety of tumor-associated Ags into human dendritic cells (DCs), culminating in their efficient presentation to T cells. We have generated a human mAb (B11) against the mannose receptor that is rapidly internalized by DCs through receptor-mediated endocytosis. By genetically linking the melanoma Ag, pmel17, to Ab B11, we obtained the fully human fusion protein, B11-pmel17. Treatment of DCs with B11-pmel17 resulted in the presentation of pmel17 in the context of HLA class I and class II molecules. Thus, potent pmel17-specific T cells were cytotoxic toward gp100(+) HLA-matched melanoma targets, but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor lines. Importantly, competitive inhibition of lysis of an otherwise susceptible melanoma cell line by cold targets pulsed with known gp100 CD8 T cell epitopes as well as a dose-dependent proliferative response to Th epitopes demonstrates that DCs can process targeted Ag for activation of cytotoxic as well as helper arms of the immune response. Thus, the specific targeting of soluble exogenous tumor Ag to the DC mannose receptor directly contributes to the generation of multiple HLA-restricted Ag-specific T cell responses.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / pharmacology
  • Antibody Specificity / genetics
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Binding Sites, Antibody / genetics
  • Binding, Competitive / genetics
  • Binding, Competitive / immunology
  • Cell Differentiation / genetics
  • Cell Differentiation / immunology
  • Cell Line, Transformed
  • Cytotoxicity, Immunologic / genetics
  • Dendritic Cells / cytology
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Epitopes, T-Lymphocyte / immunology
  • Gene Targeting* / methods
  • HLA Antigens / metabolism
  • HLA Antigens / physiology*
  • HLA-A2 Antigen / metabolism
  • HLA-A2 Antigen / physiology
  • HLA-D Antigens / physiology
  • Humans
  • Lectins, C-Type / genetics
  • Lectins, C-Type / immunology*
  • Lectins, C-Type / metabolism
  • Mannose Receptor
  • Mannose-Binding Lectins / genetics
  • Mannose-Binding Lectins / immunology*
  • Mannose-Binding Lectins / metabolism
  • Melanoma / immunology*
  • Melanoma / prevention & control
  • Membrane Glycoproteins / chemical synthesis
  • Membrane Glycoproteins / immunology
  • Mice
  • Mice, Transgenic
  • Molecular Sequence Data
  • Neoplasm Proteins / chemical synthesis
  • Neoplasm Proteins / immunology
  • Proteins / genetics
  • Proteins / immunology*
  • Proteins / physiology
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / immunology*
  • Receptors, Cell Surface / metabolism
  • Recombinant Fusion Proteins / chemical synthesis
  • Recombinant Fusion Proteins / metabolism
  • T-Lymphocytes, Cytotoxic / cytology
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / metabolism
  • T-Lymphocytes, Helper-Inducer / immunology
  • Transfection
  • gp100 Melanoma Antigen

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Epitopes, T-Lymphocyte
  • HLA Antigens
  • HLA-A2 Antigen
  • HLA-D Antigens
  • Lectins, C-Type
  • Mannose Receptor
  • Mannose-Binding Lectins
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • PMEL protein, human
  • Pmel protein, mouse
  • Proteins
  • Receptors, Cell Surface
  • Recombinant Fusion Proteins
  • gp100 Melanoma Antigen